BRACHIAL ARTERY VASOREACTIVITY
肱动脉血管反应性
基本信息
- 批准号:2685522
- 负责人:
- 金额:$ 21.52万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1997
- 资助国家:美国
- 起止时间:1997-04-17 至 2000-03-31
- 项目状态:已结题
- 来源:
- 关键词:aging atherosclerosis cardiovascular disorder diagnosis clinical research coronary disorder diagnosis design /evaluation disease /disorder proneness /risk gender difference human old age (65+) human subject longitudinal human study mathematical model myocardial infarction racial /ethnic difference vascular endothelium vasodilation
项目摘要
DESCRIPTION: (Adapted from Investigator's Abstract) Abnormalities of
arterial vasoreactivity have been linked to a multitude of cardiovascular
disease risk factors, have been shown to improve with risk factor
intervention, and have been associated with prevalent coronary artery
disease. Many of these observations have used as the index of
vasoreactivity flow-mediated arterial dilation, a non-invasively measured
parameter uniquely suited for epidemiologic investigation; this index,
however, has not been tested for its association with incident coronary
heart disease (CHD). Previously flow-mediated brachial arterial
vasoreactivity has been quantified by a single measurement of arterial
dilation measured at a fixed point in time following increase of blood flow.
Bowman Gray has developed a new method for quantifying brachial artery
vasoreactivity that promises to markedly enhance the informativeness of the
procedure by identifying not only the maximum artery responsivity but also
the time to maximum response. The proposed study will augment data already
being collected in the Cardiovascular Health Study (CHS), a multicenter NIH
funded population based study of risk factors and their relation to
prevalent and incident symptomatic CHD and other vascular disease as well as
subclinical vascular disease (e.g., asymptomatic atherosclerosis). The CHS
population was initially age 65 and older (1989-1990), and will undergo its
9th yearly examination from June, 1997 through June, 1998 (n=about 3000
participants). The investigators propose to add a measure of flow-mediated
brachial artery vasoreactivity to this examination. Analysis will quantify
associations between flow-mediated brachial artery vasoreactivity and
incident CHD over 3 years. Also of interest will be associations of
vasoreactivity with cardiovascular disease risk factors and with other
indices of subclinical vascular disease. The investigators state that it is
likely that flow-mediated brachial artery vasoreactivity, since it provides
an index of a different dimension of vascular disease than those provided by
B-mode ultrasound or ankle-arm index, will be independently related to
incident CHD.
描述:(改编自研究者摘要)
动脉血管反应性与许多心血管疾病有关,
疾病的危险因素,已被证明是改善与风险因素
介入治疗,并已与流行的冠状动脉
疾病 其中许多观察结果被用作
血管反应性血流介导的动脉扩张,一种非侵入性测量
唯一适合流行病学调查的参数;该指数,
然而,还没有测试其与冠状动脉事件的相关性,
心脏病(CHD)。 既往血流介导肱动脉
血管反应性已经通过对动脉的单次测量来量化。
在血流增加后的固定时间点测量的扩张。
Bowman Gray开发了一种新的方法来量化肱动脉
血管反应性,承诺显着提高的信息性,
不仅识别最大动脉反应性,
最大响应时间。 拟议中的研究将增加数据已经
NIH多中心心血管健康研究(CHS)正在收集数据
受资助的基于人群的风险因素及其与
流行的和偶发的有症状的CHD和其他血管疾病,以及
亚临床血管疾病(例如,无症状动脉粥样硬化)。 社区卫生服务
人口最初年龄为65岁及以上(1989-1990年),
1997年6月至1998年6月的第9次年度检查(n=约3000
参与者)。 研究人员建议增加一种测量流量介导的
肱动脉的血管反应性。 分析将量化
血流介导的肱动脉血管反应性与
3年以上CHD事件。 同样令人感兴趣的是,
血管反应性与心血管疾病危险因素和其他
亚临床血管疾病的指数。 调查人员表示,
可能是血流介导的肱动脉血管反应性,因为它提供了
血管疾病的不同维度的指数,而不是由
B超或踝臂指数,将独立相关
CHD事件。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JOHN R CROUSE其他文献
JOHN R CROUSE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JOHN R CROUSE', 18)}}的其他基金
CLINICAL TRIAL: AIM-HIGH: ATHEROSCLEROSIS INTERVENTIONIN MATABOLIC SYNDROME WIT
临床试验:志存高远:代谢综合征 WIT 中的动脉粥样硬化干预
- 批准号:
8167013 - 财政年份:2010
- 资助金额:
$ 21.52万 - 项目类别:
CLINICAL TRIAL: ACTION TO CONTROL CARDIOVASCULAR RISKS IN DIABETES (ACCORD)
临床试验:控制糖尿病心血管风险的行动(ACCORD)
- 批准号:
8167003 - 财政年份:2010
- 资助金额:
$ 21.52万 - 项目类别:
CLINICAL TRIAL: ACTION TO CONTROL CARDIOVASCULAR RISKS IN DIABETES (ACCORD)
临床试验:控制糖尿病心血管风险的行动(ACCORD)
- 批准号:
7951364 - 财政年份:2009
- 资助金额:
$ 21.52万 - 项目类别:
CLINICAL TRIAL: AIM-HIGH: ATHEROSCLEROSIS INTERVENTIONIN MATABOLIC SYNDROME WIT
临床试验:志存高远:代谢综合征 WIT 中的动脉粥样硬化干预
- 批准号:
7951381 - 财政年份:2009
- 资助金额:
$ 21.52万 - 项目类别:
CLINICAL TRIAL: CAROTID ATHEROSCLEROSIS (MRI) PROGRESSION STUDY (CAMPS)
临床试验:颈动脉粥样硬化 (MRI) 进展研究(CAMPS)
- 批准号:
7951371 - 财政年份:2009
- 资助金额:
$ 21.52万 - 项目类别:
EFFECTS ON INTIMA MEDIA THICKNESS: ROSUVASTATIN 40 MG (METEOR)
对内膜中层厚度的影响:瑞舒伐他汀 40 MG (METEOR)
- 批准号:
7607675 - 财政年份:2007
- 资助金额:
$ 21.52万 - 项目类别:
AIM-HIGH: ATHEROSCLEROSIS INTERVENTIONIN MATABOLIC SYNDROME WITH LOW HDL/HIGH
目标高:动脉粥样硬化干预低 HDL/高代谢综合征
- 批准号:
7607706 - 财政年份:2007
- 资助金额:
$ 21.52万 - 项目类别:
ACTION TO CONTROL CARDIOVASCULAR RISKS IN DIABETES (ACCORD)
控制糖尿病心血管风险的行动(协议)
- 批准号:
7607664 - 财政年份:2007
- 资助金额:
$ 21.52万 - 项目类别:
相似海外基金
Targeted ablation of cerebral atherosclerosis using supramolecular self-assembly
利用超分子自组装靶向消融脑动脉粥样硬化
- 批准号:
24K21101 - 财政年份:2024
- 资助金额:
$ 21.52万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Body composition and atherosclerosis-related biomarkers in women with endometriosis
子宫内膜异位症女性的身体成分和动脉粥样硬化相关生物标志物
- 批准号:
23K15842 - 财政年份:2023
- 资助金额:
$ 21.52万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Targeted multimodal stimuli-responsive nanogels for atherosclerosis imaging and therapy
用于动脉粥样硬化成像和治疗的靶向多模式刺激响应纳米凝胶
- 批准号:
2880683 - 财政年份:2023
- 资助金额:
$ 21.52万 - 项目类别:
Studentship
The Epigenetic Regulator Prdm16 Controls Smooth Muscle Phenotypic Modulation and Atherosclerosis Risk
表观遗传调节因子 Prdm16 控制平滑肌表型调节和动脉粥样硬化风险
- 批准号:
10537602 - 财政年份:2023
- 资助金额:
$ 21.52万 - 项目类别:
Role of IL-6 trans signaling in atherosclerosis development and late-stage pathogenesis
IL-6反式信号传导在动脉粥样硬化发展和晚期发病机制中的作用
- 批准号:
10652788 - 财政年份:2023
- 资助金额:
$ 21.52万 - 项目类别:
Novel Mechanisms Underlying the Development of Atherosclerosis
动脉粥样硬化发展的新机制
- 批准号:
10589484 - 财政年份:2023
- 资助金额:
$ 21.52万 - 项目类别:
Alcohol Regulation of Endothelial Plasticity in Atherosclerosis
酒精对动脉粥样硬化内皮可塑性的调节
- 批准号:
10585070 - 财政年份:2023
- 资助金额:
$ 21.52万 - 项目类别:
From genotype to phenotype in a GWAS locus: the role of REST in atherosclerosis
GWAS 位点从基因型到表型:REST 在动脉粥样硬化中的作用
- 批准号:
10570469 - 财政年份:2023
- 资助金额:
$ 21.52万 - 项目类别:
The role of extracellular vesicle-associated MicroRNAs in HIV-associated atherosclerosis
细胞外囊泡相关 MicroRNA 在 HIV 相关动脉粥样硬化中的作用
- 批准号:
10619831 - 财政年份:2023
- 资助金额:
$ 21.52万 - 项目类别:














{{item.name}}会员




